

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7249053

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
JANSSEN BIOTECH, INC.	03/16/2022
RECEIVING PARTY DATA	
Name:	THERAVANCE BIOPHARMA R&D IP, LLC
Street Address:	901 GATEWAY BLVD
City:	SOUTH SAN FRANCISCO
State/Country:	CALIFORNIA
Postal Code:	94080
PROPERTY NUMBERS Total: 4	
Property Type	Number
PCT Number:	US2021054004
Application Number:	17450205
Application Number:	63089928
Application Number:	62924819
CORRESPONDENCE DATA	
Fax Number:	(857)300-4001
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	857-300-4003
Email:	bostonpatent@lathropgage.com,dvincent@lathropgage.com, patricia.ford@lathropgpm.com
Correspondent Name:	BRIAN C. TRINQUE
Address Line 1:	LATHROP GPM LLP
Address Line 2:	28 STATE STREET
Address Line 4:	BOSTON, MASSACHUSETTS 02109
ATTORNEY DOCKET NUMBER:	721138: NTT-153
NAME OF SUBMITTER:	BRIAN C. TRINQUE
SIGNATURE:	/BRIAN C. TRINQUE/
DATE SIGNED:	03/28/2022
Total Attachments: 4	
source=722138-THT-153-JOINT-Janssen_Biotech_Patent_Assignment_Joint_Inventions_Executed-3-28-2022#page1.tif	

source=722138-THT-153-JOINT-Janssen_Biotech_Patent_Assignment_Joint_Inventions_Executed-3-28-2022#page2.tif
source=722138-THT-153-JOINT-Janssen_Biotech_Patent_Assignment_Joint_Inventions_Executed-3-28-2022#page3.tif
source=722138-THT-153-JOINT-Janssen_Biotech_Patent_Assignment_Joint_Inventions_Executed-3-28-2022#page4.tif

Patent Assignment

WHEREAS, **Janssen Biotech, Inc.**, a Pennsylvania corporation having its principal place of business at 800/850 Ridgeview Drive, Horsham, Pennsylvania 19044 U.S.A. (the "**Assignor**"), is a joint owner of the patents and patent applications listed in **EXHIBIT A** (such patents and patent applications and the inventions set forth therein are collectively the "**Assigned Patents**");

WHEREAS, **Theravance Biopharma R&D IP, LLC**, a limited liability company duly organized under and pursuant to the laws of Delaware and having its principal place of business at 901 Gateway Boulevard, South San Francisco, California 94080 U.S.A. (the "**Assignee**"), is also a joint owner of the Assigned Patents and is desirous of acquiring Assignor's entire right, title and interest in and to the Assigned Patents, and in and to any subsequent patent applications and patents filed or granted thereon or therefrom, and Assignor is willing to assign its rights, title, and interest with respect thereto to the Assignee on the terms hereinafter set forth;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Assignor does hereby sell, assign, transfer, set over and relinquishes exclusively unto the Assignee, its successors, legal representatives and assigns, Assignor's entire right, title and interest in and to: (i) the Assigned Patents including, to the extent of Assignor's rights, the right to file patent applications on inventions set forth in the Assigned Patents; the right to claim priority to any of the Assigned Patents; the entire right, title and interest in and to any subsequent U.S. and foreign patent applications and patents claiming priority to any of the Assigned Patents, and in and to any U.S. and foreign patent applications and patents that claim priority to a patent application or patent arising from the Assigned Patents; (ii) any U.S. and foreign patents that may be granted on or from any of the Assigned Patents; (iii) any applications, divisionals, continuations, continuations-in-part, reexaminations, reissues, registrations, renewals, revalidations, substitutions, utility models, petty patents, extensions, and supplementary protection certificates that may be filed or granted on or for any of the Assigned Patents; (iv) all accrued causes of action for infringement of any of the foregoing; and (v) all rights to and for the Assigned Patents under the Paris Convention for the Protection of Industrial Property; the same to be held and enjoyed by the Assignee, for its own use and behalf and for the use and behalf of its successors, legal representatives and assigns, to the full end of the term of the Assigned Patents and any such patents that may be granted thereon or therefrom as fully and entirely as if the same would have been held and enjoyed by the Assignor had this sale and assignment not been made.

AND for the same consideration, the Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives and assigns, that the Assignor has not executed and will not execute any assignment, sale, agreement or encumbrance in conflict with this assignment.

AND for the same consideration, the Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives and assigns that, at the Assignee's expense and reasonable request, the Assignor will take action and execute documents necessary to perfect the interest assigned herein.

AND for the same consideration, the Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives and assigns that whenever counsel for the Assignee, or the counsel for its successors, legal representatives and assigns, shall advise that any proceeding,


filing or other legal action in connection with the Assigned Patents or any patent applications and patents resulting therefrom is lawful and desirable, Assignor will, to the extent reasonable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of the Assigned Patents and patent applications and patents resulting therefrom, without charge to the Assignor, its successors, legal representatives and assigns, but at the cost and expense of the Assignee, its successors, legal representatives and assigns.

AND the Assignor hereby requests the Director of the United States Patent and Trademark Office, and all foreign patent offices, to issue any and all patents resulting from the Assigned Patents or from any patent applications filed thereon or therefrom to the Assignee for the sole use and behalf of the Assignee, its successors, legal representatives and assigns.

[the remainder of this page intentionally left blank]

IN WITNESS WHEREOF, the parties hereby have executed this assignment on the date(s) shown below.

Janssen Biotech, Inc.

By:  Date: 16 March 22

Name: Brian C. Carey

Title: Asst. Corporate Secretary

Theravance Biopharma R&D IP, LLC

By:  Date: March 18, 2022

Name: Jeffrey A. Hagenah

Title: Vice President, Legal & Chief Patent Counsel

EXHIBIT A**Title: Process for Preparing a Pan-JAK Inhibitor and Related Intermediate Compounds**

Country	Status	Application Number	Filing Date	Patent Number	Grant Date
Lebanon	Pending	12337	10/12/2021		
Patent Cooperation Treaty - (WO)	Pending	PCT/US21/53997	10/07/2021		
Taiwan	Pending	110137304	10/07/2021		
United States -- (US)	Pending	17/450,199	10/07/2021		
United States -- (US)	Expired	63/089,919	10/09/2020		
United States -- (US)	Abandoned	62/924,818	10/23/2019		
Uruguay	Pending	39,454	10/07/2021		

Title: Formulation of a Pan-JAK Inhibitor

Country	Status	Application Number	Filing Date	Patent Number	Grant Date
Lebanon	Pending	12336	10/12/2021		
Patent Cooperation Treaty - (WO)	Pending	PCT/US21/54004	10/07/2021		
Taiwan	Pending	110137305	10/07/2021		
United States -- (US)	Pending	17/450,205	10/07/2021		
United States -- (US)	Expired	63/089,928	10/09/2020		
United States -- (US)	Abandoned	62/924,819	10/23/2019		
Uruguay	Pending	39,462	10/07/2021		

[End of Exhibit A]